Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

233.87 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow 
Via Benzinga
Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground
For the bull run to continue we need broader market participation from SMID caps. 
Via Talk Markets
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) Phase 3 Clarity AD tria 
Via Benzinga
Why Are Cruise Stocks CCL, RCL, NCLH Up Today?
Cruise stocks are on the rise Monday as investors react to a positive note to clients from JPMorgan analysts and we've got the details! 
Via InvestorPlace
BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing
Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday. 
Via InvestorPlace
Expert Ratings for Biogen
Via Benzinga
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Biogen Unusual Options Activity For May 26
Via Benzinga
Nasdaq, S&amp;P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low
Via Benzinga
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
A panel of experts will debate the merits of Biogen's drug, Leqembi. 
Via Investor's Business Daily
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
Senator Bernie Sanders urged the U.S. 
Via Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for... 
Via Benzinga
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near
The FDA's advisors will consider the full approval of Leqembi on Friday. 
Via Investor's Business Daily
Analyst Ratings for Biogen
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio
When investors consider the purchase of a real estate investment trust (REIT), along with performance and dividends, they need to consider the properties and tenants that accompany that REIT. Several... 
Via Benzinga
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
The news also benefits Biogen's partner Eisai and rival Eli Lilly. 
Via Investor's Business Daily
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher. 
Via InvestorPlace
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak. 
Via The Motley Fool
Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.
An analyst says Lilly's donanemab could become a blockbuster in its second year on the market. 
Via Investor's Business Daily
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
There's no rule that says a market must have only one winner. 
Via The Motley Fool
3 Reasons to Buy Biogen Stock (and 1 to Sell)
The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi. 
Via The Motley Fool
Here’s What Eli Lilly’s Latest Clinical Win Means For Investors
The biotech's prospects continue to get brighter. 
Via The Motley Fool
Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal
Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors. 
Via The Motley Fool
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.